FDA Gives Accelerated Approval to Seagen - Genmab's ADC In Cervical Cancer

  • The FDA handed an accelerated approval to Seagen Inc SGEN and Genmab A/S’ GMAB Tivdak (tisotumab vedotin-tftv, or TV).
  • The nod comes for second-line patients with recurrent or metastatic cervical cancer who previously progressed after chemotherapy rather than PD-(L)1 systemic therapy.
  • Read Next: Seagen, Genmab Present Tisotumab Vedotin Combo Data In Cervical Cancer.
  • Tivdak is an antibody-drug conjugate (ADC) that links a tissue factor-directed antibody with a payload of monomethyl auristatin E. 
  • The agency based its review on data from the Phase II innovaTV 204 study in 101 patients, with Tivdak posting a 24% response rate, with a median duration of response of 8.3 months. 
  • Seagen and Genmab will run a confirmatory trial to determine the drug’s clinical outcomes.
  • The drug will come with a black box warning for ocular toxicity, which includes a risk of changes in the corneal epithelium and conjunctiva, resulting in vision changes, including severe vision loss and corneal ulceration to the drug’s label.
  • Related content: Benzinga's Full FDA Calendar.
  • Price Action: SGEN stock closed 1.82% higher at $159.06 on Monday, while GMAB shares are up 2.93% at $44.20 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareFDAMoversTrading IdeasGeneralBriefsCervical Cancer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!